Ensign Peak Advisors
CRDF icon

Ensign Peak Advisors’s Cardiff Oncology CRDF Stock Holding History

Ensign Peak Advisors’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-22,123
Closed -$205K – 1834
2021
Q1 		$205K Buy
22,123
+17,123
+342% +$208K ﹤0.01% 1728
2020
Q4 		$90K Hold
5,000
– – ﹤0.01% 1784
2020
Q3 		$71K Buy
+5,000
New +$33K ﹤0.01% 1717

Other funds holding CRDF

EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Ensign Peak Advisors's CRDF Position: Q2 2021 in Review

Ensign Peak Advisors sold out of Cardiff Oncology (CRDF) in Q2 2021, closing a stake of 22,123 shares — an estimated $205K sold.

Ensign Peak Advisors first reported a position in CRDF in Q3 2020 and held it in 3 quarters. The position peaked at $205K in Q1 2021. 90 funds tracked by Wall St. Rank hold CRDF as of Q2 2021.

  • Ensign Peak Advisors reported no remaining Cardiff Oncology position as of Q2 2021 after selling out during the quarter.
  • Ensign Peak Advisors sold 22,123 Cardiff Oncology shares in Q2 2021, an estimated $205K.
  • Ensign Peak Advisors first reported a position in Cardiff Oncology in Q3 2020 and held it in 3 quarters.
  • Ensign Peak Advisors's Cardiff Oncology position peaked at $205K in Q1 2021.
  • 90 funds tracked by Wall St. Rank held Cardiff Oncology as of Q2 2021.

Based on Ensign Peak Advisors's 13F filing for Q2 2021, filed 13 Aug 2021.